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Abstract
Notch pathway is a highly conserved cell signaling system that plays very important
roles in controlling multiple cell differentiation processes during embryonic and adult
life. Multiple lines of evidence support the oncogenic role of Notch signaling in
several human solid cancers; however, the pleiotropic effects and molecular
mechanisms of Notch signaling inhibition on nasopharyngeal carcinoma (NPC) remain
unclear. In this study, we evaluated Notch1 expression in NPC cell lines (CNE1, CNE2,
SUNE1, HONE1, and HK1) by real‐time quantitative PCR and Western blot analysis,
and we found that CNE1 and CNE2 cells expressed a higher level of Notch1
compared with HONE1, SUNE1, and HK1 cells. Then Notch1 expression was
specifically knocked down in CNE1 and CNE2 cells by Notch1 short hairpin RNA
(shRNA). In Notch1 knockdown cells, cell proliferation, migration, and invasion were
significantly inhibited. The epithelial‐mesenchymal transition of tumor cells was
reversed in Notch1‐shRNA‐transfected cells, accompanied by epithelioid‐like
morphology changes, increased protein levels of E‐cadherin, and decreased
expression of vimentin. In addition, knockdown of Notch1 markedly inhibited the
expression of urokinase plasminogen activator (uPA) and its receptor uPAR, and
chemokines C‐C motif chemokine ligand 2 and C‐X‐C motif chemokine ligand 16,
indicating that these factors are downstream targets of Notch1. Furthermore,
deleting uPA expression had similar effects as Notch1. Finally, knockdown of Notch1
significantly diminished CNE1 cell growth in a murine model concomitant with
inhibition of cell proliferation and induction of apoptosis. These results suggest that
Notch1 may become a novel therapeutic target for the clinical treatment of NPC.
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1 | INTRODUCTION
Nasopharyngeal carcinoma (NPC) is a disease that is rare in most parts
of the world, but is very common in both southern China with an
incidence of 10 to 20/100 000 population per year, as well as in other
Southeast Asian nations.1,2 With properties of special anatomic location,
and sensitivity to radiotherapy and chemotherapy, the first‐line for NPC
treatment in clinics is radiotherapy.3,4 However, radiotherapy is only
suitable for patients with primary tumors and localized tumors with
regional lymph node metastases. Relapse or formation of distant
metastases often occur after radiotherapy, resulting in a 5‐year survival
rate of about 50 to 60%.5 In addition, any patients with NPC develop
resistance to radiotherapy that correlates with poor prognoses.6
Therefore, the identification of novel targets and validation of potential
therapeutic approaches are urgently needed.
The Notch signaling pathway is a highly evolutionarily conserved
pathway that is involved in pleiotropic functions, such as regulating
cell differentiation, proliferation, apoptosis, and ultimately cell fate.
Notch signaling was first identified in a study of Drosophila with
serration wings by Morgan's group in 1917.7 Four Notch receptors,
namely, Notch1, Notch2, Notch3, and Notch4, and five ligands, namely,
Jagged1, Jagged2, Delta‐like ligand 1 (Dll1), Dll3, and Dll4, have been
described in mammals.8,9 In the last few decades, progress has been
made in both basic and clinical studies of Notch signaling, not only
in developmental biology but also in cancer stem cell biology.10,11
Aberrant expression of Notch signaling proteins has been reported in
a wide variety of human cancers, including T‐cell acute lymphoblastic
leukemia, the first cancer type in which Notch 1 was described
as a factor that promotes cancer development.12 The potential
mechanism of Notch signaling has recently been explored in breast
cancer,13-15 ovarian cancer,16,17 renal cell carcinoma,18 and melano-
ma.19 The overexpression of Notch receptors and ligands in cancer
correlates with a poorer prognostic profile and lower survival rates.20
However, it has also been shown that Notch signaling has growth‐
suppressive functions, suggesting that this pathway is highly context‐
dependent. The most representative evidence for Notch as a tumor
suppressor is in mice with skin cancer.21 In addition, it has been
shown that Notch has a growth‐promoting function in non‐small cell
lung cancer (NSCLC),22,23 whereas constitutively active Notch1 and
Notch2 cause profound growth arrest in small cell lung cancer
(SCLC).24 It was recently reported that microRNA 139‐5p reverses
the Notch1‐mediated epithelial‐mesenchymal transition (EMT) in
glioma.25 Despite these advances, little information regarding Notch
signaling in NPC is available, and the molecular mechanism of the
Notch pathway in this disease is poorly defined. Thus, in this study,
we investigated the role of Notch1 in NPC onset and progression.
2 | MATERIALS AND METHODS
2.1 | Reagents and antibodies
Antibodies against Notch1 (#3608), E‐cadherin (#3195), Vimentin
(#5741), β‐catenin (#8480), Slug (#9585), claudin‐1 (#13255),
Caspase3 (#9662), Caspase9 (#9502), Bcl2 (#4223), cyclin E
(#20808), and cyclin D (#2978) were purchased from Cell Signaling
Technology (Boston, MA). Anti‐human monocyte chemoattractant
protein 1 (MCP‐1/CCL2, #MAB279), C‐X‐C motif chemokine ligand
16 (CXCL16, #MAB976), urokinase plasminogen activator (uPA;
#MAB1310), and uPA receptor (uPAR; #MAB807) monoclonal
antibodies were purchased from R&D Systems (Minneapolis, MN).
All the chemical reagents and β‐actin monoclonal antibody were
purchased from Sigma (St. Louis, MO).
2.2 | Cell culture
The human NPC cell lines, CNE1, CNE2, HK1, HONE1, and SUNE1,
were kindly provided by Dr. Chao‐Nan Qian (Sun Yat‐sen University
Cancer Center, Guangzhou, China) and cultured in Dulbecco's
Modified Eagle's Medium (DMEM; Invitrogen, Carlsbad, CA) supple-
mented with 10% fetal bovine serum (FBS) and 1% penicillin‐
streptomycin solution (Invitrogen). CNE1 and HK1 cells are well‐
differentiated tumor cells, whereas CNE2, HONE1, and SUNE1 cells
are poorly differentiated tumor cells.26,27 Human nasal epithelial
cells (HNEC) were purchased from Promocell GmbH (Heidelberg,
Germany) and cultured in Airway Epithelial Cell growth medium
(Promocell GmbH). All the cell lines were grown in a humidified
incubator containing 5% CO2 at 37°C and tested to rule out
mycoplasma contamination.
2.3 | Conditioned medium
Conditioned medium (CM) was harvested from CNE1 and CNE2 cell
lines. Briefly, 2 × 106 cells were plated overnight in a 10‐cm dish in
DMEM supplemented with 10% FBS. The next day, cells were
washed twice with phosphate‐buffered saline (PBS) and the medium
was changed to DMEM with 1% FBS. The CM was collected after 48
hours. To normalize for differences in cell density because of
proliferation during the cell culture period, cells from each well
were collected and the total DNA content/well was determined.
Then, CM was normalized for DNA content between samples by
adding DMEM.
2.4 | Notch1‐shRNA transfection
shRNA molecules specific to Notch1 (sense 5′‐CCGGGCATGGTGCC
GAACCAATACACTCGAGTGTATTGGTTCGGCACCATGCTTTTTG‐3′;
antisense 5′‐AATTCAAAAAGCATGGTGCCGAACCAATACACTCGAG
TGTATTGGTTCGGCACCATGC‐3′) were designed from homo sapiens
Notch1 complete mRNA (Accession No: NM_017617.3, position
6950–6970) using Block‐iT RNAi Designer (Invitrogen). The double‐
stranded shRNA oligo was annealed and inserted into pLKO.1
lentiviral vector (Addgene, Cambridge, MA) containing the puromycin
resistance gene. Then, the recombinant construct was verified
by sequencing (Invitrogen). Lentiviral particles were assembled by
transiently co‐transfecting 293 T cells with the shRNA‐expressing
lentiviral vector, and packaging the plasmid pRRE, vesicular stomatitis
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virus envelope plasmid pMD2G, and gene transfer plasmid RSV‐REV.
CNE1 and CNE2 cells were infected with lentiviral particles (Notch1‐
shRNA and empty vector [EV], respectively) in the presence of
8 μg/mL polybrene (Sigma). Two days after infection, cells were
selected by adding puromycin (Sigma) in culture medium and
maintained for at least 2 weeks.
2.5 | uPA‐shRNA transfection
The shRNA molecules specific to uPA (sense 5′‐CCGGGCTGA
GTTTCCTGGACTTAGTCTCGAGACTAAGTCCAGGAAACTCAGCTT
TTTG‐3′; antisense 5′‐AATTCAAAAAGCTGAGTTTCCTGGACTTAGT
CTCGAG ACTAAGT CCAGGAAACTCAGC‐3′) were designed from
homo sapiens uPA complete mRNA (Accession No: NG_011904.1,
position 1784–1804) using Block‐It RNAi Designer. The procedure of
uPA‐shRNA construct and transfection please see the above
(Notch1‐shRNA transfection).
2.6 | Real‐time quantitative PCR
Total RNA was extracted with TRIzol reagent (Invitrogen), and cDNA
was synthesized from 2 μg total RNA using the SuperScript III First‐
Strand Kit (Invitrogen). The reverse transcription reaction was
conducted at 65°C for 5 minutes followed by 50°C for 50 minutes
and 70°C for 15 minutes. PCR primers for Notch1 consisted of forward
5′‐GGCACTTTCTGTGAGGAGGA‐3′ and reverse 5′‐GCAGTCAGGCGT
GTTGTTCT‐3′. PCR primers for uPA consisted of forward 5′‐AAC
TCTGCCACTGTCCTTC‐3′ and reverse 5′‐CGGTTGTCTGGGTTCC
TG‐3′. PCR primers for hairy and enhancer of split‐1 (Hes1) consisted
of forward 5′‐AGCTCGCGGCATTCCAAG‐3′ and reverse 5′‐AGCG
GGTCACCTCGTTCA‐3′. PCR Primers for glyceral‐dehyde3‐phosphate
dehydrogenase (GAPDH) consisted of forward 5′‐AGCCACATCGCT
CAGACA‐3′ and reverse 5′‐GCCCAATACGACCAAATCC‐3′. GAPDH
was used as an internal control. Real‐time quantitative PCR (qPCR) was
performed as previously described.28,29 The relative expression of
Notch1 or uPA to GAPDH was calculated using the ΔCT method.30
2.7 | Western blot analysis
Cell lysates were prepared using standard procedures.31 The
membranes were incubated at 4°C overnight with Notch1,
E‐cadherin, vimentin, β‐catenin, Slug, claudin‐1, cyclin E, and cyclin
D primary antibodies (Cell Signaling Technology). After being washed
in TBST, the membranes were incubated with the horseradish
peroxidase‐conjugated secondary antibody, and the proteins were
detected using the enhanced chemiluminescence detection system
(Thermo Fisher Scientific, Waltham, MA). As a control for equal
protein loading, β‐actin (Sigma) was visualized.
2.8 | Enzyme‐linked immunosorbent assay
To measure the protein levels of C‐C motif chemokine ligand 2 (CCL2),
CXCL16, uPA, and uPAR in CM collected from CNE1 and CNE2
wild‐type cells, the cells transfected with EV or Notch1‐shRNA was
subjected to enzyme‐linked immunosorbent assay (ELISA; R&D Systems).
ELISAs were performed according to the manufacturer's instructions.
2.9 | Cell migration and invasion assay
The cells were seeded in a 24‐well matrigel invasion chamber (BD
Biosciences, Bedford, MA), and cell migration and invasion assays
were conducted as previously described.28 After 24 hours, the cells in
the upper chamber were removed, and cells that invaded through the
matrigel matrix membrane were stained with crystal violet after
being fixed in paraformaldehyde. Then, the numbers of cells that
penetrated the membrane in 10 microscopic fields were quantified
by counting at a 200× magnification per filter. The invasive ability
was defined as the proportion of cells that penetrated the Matrigel‐
coated membrane to the number of cells that migrated through the
uncoated membrane (baseline migration).
2.10 | Cell proliferation assay
Cell proliferation was measured using the CellTiter 96 AQeous
Nonradioactive Cell Proliferation Assay (Promega, Madison, WI)
according to the manufacturer's instructions. Briefly, the cells were
plated in 96‐well plates at a density of 2000 cells/well, in 100 μL DMEM
containing 10% FBS. The cells were incubated at 37°C in a humidified
5% CO2 atmosphere for 24, 48, and 72 hours and then, 20 μL MTS
solution was added. After incubation for 2 hours at 37°C, the absorbance
of each well at 490 nm was recorded by an ELISA plate reader.
2.11 | Terminal deoxynucleotidyl transferase dUTP
nick‐end labeling assay
The terminal deoxynucleotidyl transferase dUTP nick‐end labeling
(TUNEL) assay was performed with the In Situ Cell Death Detection
kit (Roche, Indianapolis, IN) according to the manufacturer's instruc-
tions. Briefly, the cells were plated in an 8‐chamber Poly‐L‐Lysine
vessel tissue culture‐treated glass slide (BD Biosciences), cultured for
48 hours, and fixed in 4% paraformaldehyde for 1 hour at room
temperature (RT). After washing with PBS, the cells were incubated in
blocking buffer (3%H2O2 in methanol) for 15 minutes at RT. Then, the
cells were rinsed with PBS and incubated in a permeable solution
(0.1% Triton X‐100 in 0.1% sodium citrate, freshly prepared) for 2
minutes on ice. Next, the cells were incubated with TUNEL reaction
mixture for 1 hour at 37°C in a humidified chamber, followed by
restaining with Hoechst 33342 (Sigma). As a positive control, fixed and
permeabilized cells were treated with DNase I (Sigma) for 10 minutes;
as a negative control, fixed and permeabilized cells were incubated
with label solution only. The coverslips were mounted with PBS
containing Antifade Mounting Medium (Vector Lab, Burlingame, CA)
and pictures were taken under a fluorescence microscope. The
percentage of apoptotic cells with DNA nick end‐labeling was
measured by counting cells exhibiting green fluorescent nuclei at
200× in 10 randomly chosen fields in triplicate plates.
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2.12 | In vivo tumor models
The animal protocol was approved by the Institutional Animal Care
and Use Committee (Guangxi Medical University, Guangxi, China).
Nude mice were from Animal Central of Guangxi Medical University
and housed under specific pathogen‐free conditions in accordance
with the National Institute of Health guidelines. Thirty nude
mice were used in these experiments (age: 5‐6 weeks). CNE1
wild‐type cells, and cells transfected with Notch1‐shRNA or
EV were subcutaneously injected into the right flank of the mice (n
= 10 mice/group). Tumor growth was monitored when it was
palpable, and two perpendicular axes were measured using a caliper
twice a week. Tumor volume was calculated using the formula:
volume = length × width2/2.32,33 The tumor cells were allowed to
grow for 4 weeks, at which time the mice were killed, and the tumor
tissue was collected.
2.13 | Statistical analysis
Numerical data are expressed as mean ± standard deviation (SD)
or mean ± standard error of the mean (SEM), as indicated in the
figure legends. The calculations were done using the Stat View
system (Abacus Concepts, Berkeley, CA). One‐way analysis of
variance was used for all the studies. Fisher's least‐significant
difference was used for the post‐hoc analysis. P < .05 was
statistically significant.
3 | RESULTS
3.1 | Notch1 expresses significantly higher levels in
NPC tissues and cell lines
The analysis of the gene expression data sets from Gene Expression
Omnibus (GEO) database34 revealed that Notch1 expression levels
were significantly higher in NPC tissues than in normal nasophar-
yngeal tissues (Figure 1A). To confirm that the Notch1 pathway plays
key roles in NPC development, we measured Notch1 expression levels
in normal nasal epithelial cells (HNEC) and the NPC cell lines, CNE1,
HK1, CNE2, HONE1, and SUNE1, by qPCR and Western blot analysis.
We found that all NPC cell lines (CNE1, HK1, CNE2, HONE1, and
SUNE1) expressed Notch1 gene and protein (Figure 1B,C) at higher
levels compared with the HNECs. Notch1 protein levels in CNE1 and
CNE2 cells were much higher than in other NPC cell lines, prompting
us to select these two cell lines for subsequent studies.
3.2 | Knockdown of Notch1 expression inhibits
NPC cell growth and induces cell apoptosis
To investigate whether Notch1 might be an effective therapeutic
target for NPC, we used shRNA to knockdown Notch1 gene expression
in CNE1 and CNE2 cells. qPCR and Western blot analysis were
conducted to confirm the knockdown efficiency. Notch1 expression
was reduced by over 80% in cells transfected with Notch1‐shRNA
F IGURE 1 Constitutive expression of Notch1 in NPC tissues and cell lines. A, The scatterplot shows that the Notch1 gene was highly
expressed in NPC tissues by Human Genome U133 Plus 2.0 Array.34 Total RNA extracted from laser‐captured epithelium from 31 NPCs and 10
normal healthy nasopharyngeal tissue specimens. Sample data includes T stage, N stage, and race/ethnicity. B, Notch1 expression in HNEC,
SUNE1, HONE1, CNE2, CNE1, and HK1 cells was measured. Total RNA was extracted from the indicated cells and Notch1 mRNA expression
was detected by qPCR. C, Cell lysates collected from HNEC, SUNE1, HONE1, CNE2, CNE1, and HK1 cells, Notch1 protein levels assayed by
Western blot analysis from three independent experiments. WT, wild‐type cells; EV, cells transfected with empty vector; Notch1‐shRNA, cells
transfected with Notch1‐shRNA. NPC, nasopharyngeal carcinoma
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compared with those transfected with EV (Figure 2A). We further
detected Hes1 expression, which is the downstream target of Notch1
signaling, and found that Hes1 expression was dramatically reduced in
Notch1 knockdown NPC cells (Figure S1A). To observe the effects
of Notch1 knockdown on NPC cell growth, cell proliferation was
evaluated by the MTS cell proliferation assay. CNE1 and CNE2 wild‐
type cells, and cells transfected with Notch1‐shRNA or EV control
were cultured for the indicated time points, and the results were
recorded using an ELISA plate reader (Figure 2B). Lack of Notch1
expression significantly inhibited NPC cell proliferation. To elucidate
the mechanism of growth inhibition in Notch1 knockdown cells, we
examined cell apoptosis using the TUNEL assay. We found that cells
with lower Notch1 expression had a higher apoptosis rate than
EV‐transfected control cells (Figure 2C). Notch1 knockdown caused
40 to 60% apoptosis whereas control cells only showed 5 to 10%
apoptosis, suggesting that the growth inhibitory effects on Notch1
knockdown cells were partially because of the induction of apoptosis.
Western blot results showed that the apoptotic‐related proteins were
F IGURE 2 Downregulation of Notch1 expression inhibits NPC cell growth and induces apoptosis. A, The knockdown efficiency of Notch1 in
CNE1 and CNE2 cells, compared with EV control cells. qPCR (left panel) and Western blot analysis (right panel) were performed. B, The
proliferation of the NPC cell lines, CNE2 (upper panel) and CNE1 (lower panel), were determined by the MTS assay. C, Representative
micrographs and quantitative data for NPC cell apoptosis determined by the TUNEL assay. The TUNEL assay was conducted as outlined in the
Materials and Methods. Fragmented DNA was labeled in green, and all nuclei were counterstained with Hoechst 33342. Knockdown of Notch1
expression increased apoptosis about 3.5‐5 folds compared with controls. D, Downregulation of Notch1 inhibited NPC tumorigenesis in the
mouse model. Tumor cells were subcutaneously injected into nude mice and the tumor volume was calculated twice a week. All the data are
from three separate experiments. Columns, mean of triplicates; bars, SEM. GAPDH was used as an internal control. *P < .05, and **P < .01,
respectively, indicates a significant difference compared with the EV control. EV, empty vector; NPC, nasopharyngeal carcinoma; TUNEL,
terminal deoxynucleotidyl transferase dUTP nick‐end labeling [Color figure can be viewed at wileyonlinelibrary.com]
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changed. The total and cleavage Caspase9 were increased and Bcl2
levels were decreased in Notch1‐shRNA cells (Figure S1B).
3.3 | Downregulation of Notch1 expression inhibits
CNE1 cell growth in vivo
To explore the probability of tumor cell growth in vivo after
Notch1 expression was knocked down, we subcutaneously injected
CNE1 wild‐type cells, the cells transfected with EV that expressed
Notch1 normally, and the cells transfected with Notch1‐shRNA
(inhibition of Notch1 expression) into nude mice. After 4 weeks,
tumors were harvested and kept in 10% formalin for further study. The
results showed that knocking down Notch1 expression significantly
inhibited tumorigenesis and growth compared with the controls (Figure
2D and Table 1). Together, these results indicate that the Notch1
pathway is highly expressed in NPC tissues and cell lines, and promotes
tumor cell growth both in vitro and in vivo. Thus, Notch1 may be a
novel valuable therapeutic target for NPC treatment.
3.4 | Reducing Notch1 expression diminishes
tumor cell migration and invasion
To investigate the changes of biological functions in Notch1 knock-
down NPC cells, we used the transwell assay to assess NPC cell
migration and invasion in vitro. Cell migration was determined by
counting the number of cells that penetrated from the top to bottom
through a porous membrane, whereas in the cell invasion assay, cells
were counted that invaded the barrier of the reconstituted matrigel
layer on the membrane. Reducing Notch1 expression in CNE1 and
CNE2 cells significantly diminished cell migration (CNE1 68%, CNE2
72%) and invasion (CNE1 35%, CNE2 54%) compared with wild‐type
cells or EV‐transfected cells (Figure 3).
TABLE 1 Tumor formation in nude mice (CNE1 cells)
Group Tumor volume, mm3 (mean ± SEM) P
WT 41.11 ± 1.8
EV 56.05 ± 3.7 0.018
Notch1‐shRNA 27.21 ± 2.0
F IGURE 3 Knockdown of Notch1
expression diminishes NPC cell migration
and invasion. A, Notch1
shRNA‐transfected cells resulted in low
penetration of cells through the absent or
present matrigel‐coated membrane,
compared with the control. B,
Representative of cell migration, the cells
that migrated to the lower chambers were
counted. C, Cell penetration through the
membrane with Matrigel was quantified by
counting the numbers of cells that
penetrated the membrane in five
microscopic fields (at 200× magnification)
per filter. Invasive index (%) was defined as
the proportion of cells that penetrated the
Matrigel‐coated membrane divided by
the number of cells that migrated through
the uncoated membrane (baseline
migration). Columns, mean of triplicate
assays; bars, SEM. *P < .05, and **P < .01,
respectively, indicates a significant
difference compared with the EV control.
All the data are from three separate
experiments. EV, empty vector; NPC,
nasopharyngeal carcinoma [Color figure
can be viewed at wileyonlinelibrary.com]
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3.5 | Inhibition of Notch1 expression reverses the
EMT in NPC cells
We observed that the morphology of NPC cells changed from
spindle‐shaped into epithelioid‐like cells when Notch1 expression
was decreased (Figure 4A). To determine the molecular mechanisms
underlying the correlation of Notch1 expression with the EMT in
cancer cells, we monitored EMT marker changes in NPC wild‐type
cells and cells transfected with Notch1‐shRNA or EV by Western blot
analysis. We found that inhibition of Notch1 in both CNE2 and CNE1
cells significantly enhanced E‐cadherin and β‐catenin expression and
decreased vimentin expression (Figure 4B). These results indicate
that Notch1 knockdown might disrupt the migration and invasion of
NPC cells by reversing EMT alterations in cancer cells.
3.6 | Knockdown of Notch1 decreases CCL2 and
CXCL16 secretion
We previously demonstrated that downregulation of CCL2 or
CXCL16 significantly diminishes prostate cancer (PCa) tumor growth
both in vitro and in vivo.35-37 Knocking down CCL2 production in PCa
cells notably reduces PCa CM‐induced osteoclast formation in
vitro.36 Bone metastasis is a very common event in patients with
advanced NPC and PCa and is also the main cause of death in NPC.
To extend these observations, we determined if Notch1 knockdown
in NPC cell clones affected the expression of CCL2 and CXCL16. In
Notch1 knockdown cells, the expression of CCL2 and CXCL16 was
markedly inhibited (Figure 5A,B), indicating that they might be
downstream targets of Notch1 in patients with advanced NPC. When
CCL2 expression was knocked down38 in CNE1 cells, the level of
Notch1 did not show apparent change. Further, we overexpressed
active Notch1 intracellular domain (NICD‐Ov) in CNE1 cells,
collected the supernatants from either NICD‐Ov cells or control
cells. The CCL2 expression level was significantly increased in NICD‐
Ov cells (Figure S2).
3.7 | Knockdown of Notch1 reduces the production
of uPA and uPAR
It had been reported that uPA might act as a downstream target of
Notch signaling in PCa.39 Hence, to further explore the potential
mechanisms of Notch1 knockdown on invasion inhibition of tumor
cells, we examined the protein levels of uPA and uPAR by ELISA. We
found that the soluble uPAR was markedly reduced in Notch1
knockdown cells compared with the EV control (Figure 5C). The
protein level of uPA in CNE1 cells was also significantly decreased
after Notch1 knockdown (Figure 5D). However, uPA expression in
F IGURE 4 Knockdown of Notch1
expression in NPC cells inhibits the EMT.
A, Knockdown of Notch1 leads to cell
morphology changes. Top, morphological
changes in CNE2 cells; bottom, the
morphology of CNE1 cells changed from
spindle‐shaped into epithelioid‐like cells. B,
Notch1 shRNA‐transfected cells resulted
in the significant upregulation of E‐
cadherin protein expression and a
reduction of Vimentin and Slug expression
levels from three
independent experiments. EMT, epithelial‐
mesenchymal transition; EV, empty vector;
NPC, nasopharyngeal carcinoma
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CNE2 cells was too low to detect and was also undetectable in
Notch1 knockdown cells. Together, these results indicate that
Notch1 regulation of uPA and uPAR secretion may be a mechanism,
at least in part, for the migration and invasion of NPC cells.
3.8 | uPA acts as a key mediator in Notch1‐induced
NPC cell proliferation and invasion
To confirm the effects of uPA in Notch1‐induced NPC cell prolifera-
tion and invasion, we did a literature search in the GEO database,34
and found that uPA gene expression levels were much higher in NPC
tissues than in normal nasopharyngeal tissues (Figure 6A).34 Using
qPCR and Western blot, we observed that uPA expression level was
greater in CNE1 and HK1 cells than in HNEC or CNE2 cells (Figure
S3). Furthermore, we downregulated uPA expression in CNE1 cells by
uPA‐shRNA. The uPA gene expression was evaluated using qPCR in
CNE1 wild‐type cells, and cells transfected with EV or uPA‐shRNA
(Figure 6B). In functional studies, downregulation of uPA expression
markedly retarded tumor cell growth, decreased cyclin D and cyclin E
protein levels, and reversed the EMT. Knockdown of uPA expression
significantly reduced tumor cell invasion (Figure 6C‐E). Taken
together, these results indicate that knockdown of Notch1 expression
significantly reduces uPA production, and that downregulation of uPA
has similar effects on tumor cell growth, progression, and metastasis.
4 | DISCUSSION
Dysregulation of Notch signaling has been detected in various types
of human cancers, including breast,13,15 lung,22,23 and brain
cancers.40 It has also been reported that Notch signaling positively
correlates with the proliferation of NPC. Suppression of all Notch
receptors (Notch1–4) using GSI (γ‐secretase inhibitor) inhibit human
NPC cell proliferation37 and enhances the radiosensitivity of NPC
cells.41 In this study, we analyzed the impact of Notch1 on the onset
and progression of NPC. We first determined Notch1 expression
levels in different NPC cell lines (HONE1, SUNE1, CNE1, CNE2, and
HK1) and normal HNEC, and observed that all the tested NPC cell
lines expressed a higher level of Notch1 mRNA and protein
compared with the normal cells. We chose CNE1 and CNE2 cell
lines for further studies, as Notch1 protein levels were more highly
expressed in those cell lines. We found that the targeted disruption
of Notch1 in CNE1 and CNE2 cells by shRNA resulted in significant
inhibition of cell proliferation and induction of apoptosis. Down-
regulation of Notch1 decreased cell invasion across the artificial
matrix, which mimics the in vivo extracellular matrix. Thus, our
results provide in vitro evidence to support the role of Notch1 as an
oncogene rather than a tumor suppressor gene in NPC cells.
Furthermore, the downregulation of Notch1 inhibits tumor formation
and growth in vivo.
F IGURE 5 Inhibition of Notch1 expression decreases the production of CCL2, CXCL16, uPA, and uPAR. A, The expression of CCL2 protein
was significantly inhibited in Notch1 shRNA‐transfected cells. B, The expression of CXCL16 in CNE2 cells was decreased by more than half in
Notch1 shRNA‐transfected cells compared with the control cells. In CNE1 cells, knockdown of Notch1 expression also led to a decrease
of CXCL16, but the result was not significantly different. C, The expression of the uPAR protein was markedly inhibited in Notch1
shRNA‐transfected cells. D, Knockdown of Notch1 decreased uPA expression by about two‐fold. Columns, mean of triplicate assays; bars,
SEM. * and ** represent P < .05, and P < .01, respectively, indicates a significant difference compared with the EV control. All the data are from at
least three independent experiments. EV, empty vector; uPAR, urokinase plasminogen activator receptor
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The EMT is involved in the metastasis and progression of
tumors.42,43 The most representative marker in the process of epithelial
morphogenesis is E‐cadherin expression, as the repression and/or
delocalization of E‐cadherin is usually associated with adherent junctions
disassembly44 and enhanced cell invasiveness.45 The activation of Notch
signaling contributes to the acquisition of the EMT in both breast 46 and
pancreatic cancers.47 In this study, we found that Notch1 knockdown
markedly diminishes NPC cell migration and invasion. We also observed
the upregulation of E‐cadherin protein expression along with the
reduction of Vimentin levels in Notch1 knockdown cells.
In addition to EMT effector molecules controlling the cell invasion
and metastasis, the uPA/uPAR axis has been implicated in the
destruction of the basement membrane and extracellular matrix, which
is associated with tumor cell invasion.33,48,49 Several studies have
reported that the downregulation of Notch1 or Jagged1 decreases the
expression and activity of uPA, which contributes to the inhibition of
cancer cell migration, invasion, and apoptosis in glioblastoma,50 breast
cancer,51 and PCa cells.39 Here, we provided evidence that the Notch1
pathway might associate closely with the uPA/uPAR axis. Using qPCR
and Western blot, we observed that uPA expression level was greater
in CNE1 and HK1 cells than in HNEC or CNE2 cells. These results
prompt that uPA levels may play an important role in nasopharyngeal
carcinogenesis. In agreement with others, we showed that uPA
transcription was downregulated in Notch1‐specific knockdown cells.
Overall, these results suggest that knockdown Notch1 attenuates cell
migration and invasion, at least in part, by inhibiting the expression and
activity of the uPA/uPAR axis. To the best of our knowledge, this is the
first report to demonstrate a direct link between activation of the
uPA/uPAR axis and Notch signaling in NPC development.
We also observed that the Notch1 pathway affected the
secretion of chemokines CCL2 and CXCL16 in NPC cells. Notch
signaling directly regulates the expression of two powerful pro‐
inflammatory cytokines, interleukin 1 beta, and CCL2, in basal‐like
breast cancer, leading to the recruitment of tumor‐associated
macrophages to support tumor growth and metastasis.52 Previous
works have reported that CCL2 is associated with PCa bone
metastasis.36,38 CCL2 knockdown using shRNA approach diminished
PCa cell invasion and PCa CM‐induced osteoclast formation.
F IGURE 6 uPA acts as a key mediator in Notch1‐induced NPC cell proliferation and invasion. A, The scatterplot shows that uPA gene was
highly expressed in NPC tissues by Human Genome U133 Plus 2.0 Array.34 B, The knockdown efficiency of uPA in CNE1 cells, compared with
EV control cells, was determined by qPCR. C, CNE1 cell proliferation was examined by the MTS assay. D, uPA‐shRNA‐transfected cells resulted
in the significant upregulation of E‐cadherin protein expression and a reduction in vimentin expression. Cyclin D and cyclin E expression were
markedly decreased in uPA knockdown cells. E, uPA‐shRNA‐transfected cells (left panel) resulted in the low penetration of cells through the
Matrigel‐coated membrane, compared with control cells. Invasive Index (%) was calculated (right panel) according to the manufacturer's
instructions. The data are from three independent experiments. Columns, mean of triplicate assays; bars, SEM. EV, empty vector; NPC,
nasopharyngeal carcinoma; shRNA, short hairpin RNA; uPA, urokinase plasminogen activator. *P < .05, and **P < .01, respectively, indicates a
significant difference compared with the EV control [Color figure can be viewed at wileyonlinelibrary.com]
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Similarly, recent evidence from Xiang's group indicated that the
serum concentration of CCL2 in patients with NPC with large skull
base invasion were higher than those without or with small skull
invasion.53 Collectively, these works highlight the promoting effect of
CCL2 in tumor bone metastasis. In this study, the reduction of CCL2
and CXCL16 expression in Notch1 knockdown cells was observed,
suggesting that Notch1 can also regulate the production of CCL2 and
CXCL16, which might be involved with advanced NPC progression.
We further knocked down CCL2 expression in CNE1 cells, the level
of Notch1 did not show apparent change. Moreover, overexpression
of NICD in CNE1 cells significantly increased CCL2 level compared
with the control cells. Additional studies on the mechanisms of
Notch1 and CCL2 in NPC bone metastasis are warranted.
5 | CONCLUSIONS
This is the first report to explore the role of Notch1 in the onset and
progression of NPC. We showed that Notch1 knockdown reduced
NPC cell migration and invasion in vitro by reversing the EMT, and
decreasing the expression of uPA/uPAR and the chemokines CCL2
and CXCL16. These results indicate that the Notch1 gene may be a
novel therapeutic target for NPC treatment.
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